On the 28th, the Ministry of Food and Drug Safety (MFDS) under Director‑General Oh Yu‑kyung announced a revision to the guidance for priority‑review designation applications. The amendment allows patient experience data—such as self‑reported symptoms, quality‑of‑life measures, treatment preferences, patient and caregiver interviews, patient‑generated videos, and written comments—to be used as reference material in the evaluation of Global Innovation Products Fast‑Track (GIFT) designation for rare and severe disease therapies. This change aims to capture real‑world patient perspectives that are difficult to reflect through clinical trial metrics alone, enhancing the assessment process for innovative treatments.
Regulatory UpdatesSep 9, 2026•1 min read
Korea MFDS Expands GIFT Review to Include Patient Experience Data
The Korean MFDS revised its GIFT fast‑track guidelines, permitting patient‑reported symptoms, quality‑of‑life data, preferences, interviews, videos and written opinions as reference material for priority review of rare disease drugs.
Compiled by the PharmaCountry team · Source: KPA News
Ratings
(0)
(0)
(0)
(0)
(0)
More articles
View all insightsResearch & Reports
Global Finished Dosage Manufacturing Landscape 2026
Oct 5, 2026
Regulatory UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
Sep 28, 2026
AnalysisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
Sep 28, 2026
Leave your rating